【摘 要】
：
Purpose:The aim of this study was to evaluate i) differences in the HLA groups of renal cell carcinoma (RCC) patients and healthy control persons and ii) to study association of expression of uPA-fami
【机 构】
：
Institute of Transfusion Medicine, Martin-Luther-University Halle-Wittenberg, Germany
【出 处】
：
BITs 3rd Annual World Cancer Congress-2012(2012第五届世界癌症大会)
论文部分内容阅读
Purpose:The aim of this study was to evaluate i) differences in the HLA groups of renal cell carcinoma (RCC) patients and healthy control persons and ii) to study association of expression of uPA-family members and clinical factors in RCC patients.Methods:Peripheral blood samples from 91 RCC patients and from 203 healthy individuals used as controls were investigated for the incidence of HLA groups.In addition, tumors and adjacent normal tissue of 39 RCC patients were studied for the expression uPA, uPAR and PAI-1 on the protein level by ELISA.Expression levels were correlated with clinical data of the RCC patients.Results:We detected two HLA groups, HLA-Cw*7 and HLA-DRB 1*4 that were significantly higher in healthy test persons (34.6 % and 15.0 %) than in RCC patients (25.0 %, RR =0.7, p < 0.05 and 8.0 %;RR =0.5, p < 0.05), respectively.The detection levels for uPA and uPAR were 0.020 ng/ml, and for PAI-I 0.050 ng/ml.Elevated uPA and increased uPAR but not PAI-1 protein levels were significantly correlated with tumor size (p < 0.02 and p < 0.03), tumor grade (p < 0.04 and p < 0.05) and occurrence of metastases (p < 0.05 and p < 0.01;2-tests), respectively.RCC patients with an elevated expression of uPAR showed a 3yrs-survival rate of 53.5 % whereas patients with a normal expression possessed a rate of 83.3 % (p =0.12, Kaplan-Meier analysis) and showed a 2.8-fold but not significantly increased risk of tumor-related death (p =0.14, univariate Coxs regression analysis).Conclusion:There are HLA groups that occur less often in RCC patients than in healthy control persons.But it needs larger study populations and further immunological studies to investigate if special HLA-types can have a protective effect against RCC tumorigenesis.Elevated protein expression of uPA and uPAR is associated with major clinical factors, i.e., tumor size, tumor grade and metastases.
其他文献
It has been more than one decade since we started carbon ion radiation therapy (CIRT) for non-small cell lung cancer(NSCLC) November in 1994.From 1994 to 1999, we conducted a phase Ⅰ/Ⅱ clinical trial
The need for radiotherapy (RT) treatment is growing and is estimated to outweigh by 10 times the supply.Therefore,the availability of treatments effective in optimizing the delivery of radiations is a
Lung cancer remains the leading cause of cancer death in the United States and worldwide.More than 200,000 Americans died every year of lung cancer.At the time of presentation of Non-Small Cell Lung C
The successful development of the YICHAO Meridian is based on a Meridian theory of traditional Chinese medicine,and referred to a variety of manufacturing principles of modem medical devices, which we
Hypofractioned radiation therapy regiments are increasing being used to treat patients desiring breast conserving therapy.Shortened treatment regiments have been shown to improve quality of life and i
Objectives: In this study, we used female rats, which were treated with 7,12-dimethylbenz(a)anthracene (DMBA) to induce breast tumors and with the concomitant of alcohol intake.The role of alcohol in
In this study, perioperative outcomes and survival data in patients with cervical cancer operated with three surgical methods: robot-assisted, laparoscopic and open, are to be analyzed.From January 20
For many decades, adjuvant radiotherapy has been used after mastectomy for patients with locally advanced breast cancer.By reducing the risk of recurrency, radiotherapy can improve the overall surviva
Chemotherapy-induced nausea and vomiting (CINV) is experienced by around 80% of patients currently receiving chemotherapy.Acute CINV typically occurs within minutes or hours of drug administration, la
Background: Multidrug resistance is the most frequent type of resistance to anticancer chemotherapy and diseasemodifying antirheumatic drugs (DMARDs), which usually results from the overexpression of